Good morning, ladies and gentlemen, and welcome to the Bio-Path Holdings Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will be opening the call up for your questions. At this time, I'd like to turn the floor over to Will O'Connor of Stern Investor Relations. Please proceed. Thank you, operator. Welcome to the Bio-Path Holdings conference call and webcast to review the company's second quarter 2022 financial results and to provide an update on recent pipeline and corporate development. Earlier, we issued a press release which outlines the topics that we plan to discuss on today's call. The release is available at biopathholdings.com. With me today from Bio-Path are President and CEO, Peter Nielsen, and Senior Vice President of Finance, Accounting, and Administration, Anthony Price. Before we begin, I'd like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we urge you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Bio-Path's CEO, Peter Nielsen. Thanks, Will. Good morning, everyone, and thank you for joining us. The first half of 2022 was marked by execution across our entire organization, and I am pleased to report the progress we have made to date. Throughout the second quarter and in recent weeks, we have made substantial operational progress as we continue to advance our DNAbilize platform of products along the clinical pathway. Toward that end, we look forward to initiating our phase 1 studies of BP1001-A, a drug product modification of prexigebersen for the treatment of solid tumors, and of BP1002 to treat relapse-refractory acute myeloid leukemia, or AML, including venetoclax-resistant patients in the coming weeks. This progress is highlighted in today's announcement of the pending initiation of our phase 1/1b studies of these two products. I'll describe the importance of these two milestones in more detail later in the call. Moving now to our clinical programs and our lead product candidate, prexigebersen. We continue to make significant progress advancing stage two of our phase 2 clinical trial of prexigebersen for the treatment of acute myeloid leukemia in combination with frontline therapy decitabine and venetoclax. As you know, phase 2 clinical development of prexigebersen in AML commenced with stage one of the phase 2 clinical trial, which was open label and treated de novo AML patients with a combination of prexigebersen and low-dose cytarabine or LDAC. The combination of prexigebersen and LDAC was shown to be safe and more efficacious to treat this class of patients than with LDAC alone. As we have highlighted before, there's been an evolving landscape for standard of care in AML. Despite these new therapies, there are still patients who are refractory or resistant, and those are the patients we aim to help. As standard of care evolved, we adapted our trial design to reflect these changes. The amended stage two of this phase 2 trial in AML is an open label phase 2-stage multicenter study of prexigebersen in combination with decitabine and venetoclax in two cohorts of patients with previously untreated AML and relapsed resistant AML. A third cohort includes treating relapse-resistant AML patients who are venetoclax resistant or intolerant with the two-drug combination of prexigebersen and decitabine. The primary endpoint for the study will be the number of patients who achieve complete remission, which includes complete remission with incomplete hematologic recovery and complete remission with partial hematologic recovery. An interim analysis will be performed on each cohort to assess the safety and efficacy of the treatment. Next, I'd like to turn to our plan to phase 1 clinical trial of BP1001-A in patients with advanced solid tumors, including ovarian, uterine, pancreatic, and hormone-refractory breast cancer. BP1001-A, a fourth drug, Bio-Path drug candidate is a modified product from prexigebersen sharing the same drug substance with enhanced nanoparticle properties. You will recall that last year the FDA cleared our investigational new drug or IND application to initiate a phase 1/1B clinical trial of BP1001-A in patients with solid tumors, including ovarian, endometrial, pancreatic, and triple-negative breast cancer. This trial will be conducted at several leading cancer centers and is planned initially to evaluate the safety of prexigebersen in solid tumor patients. Patients diagnosed with recurrent ovarian and endometrial cancer often have poor outcomes, and it is our hope that prexigebersen may provide clinical benefit for such patients. We look forward to bringing this exciting program into the clinic in the coming weeks. Turning now to BP1002, our second therapeutic candidate, which targets BCL-2. As you know, BCL-2 is responsible for driving cell survival in up to 60% of all cancers. High expression of BCL-2 has been correlated with poor prognosis for patients diagnosed with AML. Venetoclax has shown activity against the anti-apoptotic protein BCL-2 and works by neutralizing the protein's BH3 domain. It is an approved treatment for chronic lymphocytic leukemia or CLL patients and untreated AML patients. However, with the exception of some patients treated with allogeneic hematopoietic cell transplantation, disease relapse invariably occurs, oftentimes due to BH3 domain mutation over time. BP1002 also targets the BCL-2 protein. However, BP1002 activity is based on blocking the BCL-2 messenger RNA and not the BH3 domain. As a result, we believe BP1002 could provide an alternative for venetoclax patients who have relapsed, including AML patients who previously received venetoclax treatments. As I mentioned earlier, we will initiate in a few weeks a phase 1b study and intend to conduct it at leading cancer centers in the United States, including the Weill Cornell Medical College, the University of Texas MD Anderson Cancer Center, the Georgia Cancer Center, and the UCLA Jonsson Comprehensive Cancer Center. A total of 60 evaluable patients will be treated with BP1002 monotherapy in a standard 3 + 3 design with a starting dose of 20 milligrams per square meter. The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over 28 days. The phase 1-B portion of the study will commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory relapsed AML patients. We hope to be able to provide incremental updates on this program as we establish safety first, followed then by efficacy in these smaller patient cohorts. Finally, let's review progress we've made with our third drug candidate, BP1003, which targets the STAT3 program. STAT3 is a transcription factor that regulates various tumorigenic processes such as tumor proliferation, metastasis, drug resistance. Its overexpression and aberrant activation characterize many cancers including breast, lung, ovarian, liver, and colon cancer. Activation of the STAT3 pathway in breast and ovarian cancer cells promotes tumor initiation, migration, and Taxol resistance. The STAT3 also contributes and promotes 5-FU resistance in colorectal cancer cells. Its role in numerous malignancies make STAT3 a potential cancer therapeutic agent. BP1003 is a novel liposome-incorporated STAT3 antisense oligonucleotide that efficiently reduces STAT3 expression and enhances the sensitivity of breast and ovarian cancer cells to Taxol and 5-FU. These results are in line with previous work in which BP1003 plus gemcitabine displayed enhanced antitumor activity in pancreatic ductal adenocarcinoma. Together, these results strongly suggest that BP1003 combination therapy is a novel strategy for patients with advanced solid tumors. In April, we were delighted to present supportive preclinical data from this program at the 2022 American Association for Cancer Research annual meeting before an audience of world-leading cancer researchers and physicians. Dr. Maria Gagliardi, a research scientist on our team, highlighted preclinical studies of BP1003 in combination with paclitaxel or fluorouracil. As a potential treatment against breast and ovarian cancer cells. We are particularly excited to launch our first in human validation of this cutting edge therapy in an especially challenging cancer indication that has limited treatment options. Our goal is to file an IND application for this very promising product candidate late in the fourth quarter or the first quarter of 2023. The timing is determined by finalizing pre-clinical testing of drug substance presence in the animal species used in testing. With that, I'll now turn the program over to Anthony Price for a brief review of our second quarter 2022 financials, along with balance sheet highlights. Anthony? Thanks, Peter. The company reported a net loss of $3.0 million or $0.42 per share for the three months ended June 30, 2022, compared to a net loss of $1.8 million or $0.26 per share for the three months ended June 30, 2021. Research and development expense for the three months ended June 30, 2022 increased to $1.9 million compared to $0.8 million for the three months ended June 30, 2021, primarily due to manufacturing expenses related to drug product releases in the second quarter of 2022 and increased patient enrollment related to our phase 2 clinical trial for prexigebersen in AML. General and administrative expense for the three months ended June 30, 2022 was $1.2 million, an increase of $0.1 million compared to the three months ended June 30, 2021, primarily due to increased legal fees. As of June 30, 2022, the company had cash of $17.0 million compared to $23.8 million at December 31, 2021. Net cash used in operating activities for the six months ended June 30, 2022 was $6.7 million compared to $4.2 million for the comparable period in 2021. With that, I'll now turn the call back over to Peter. Thanks, Anthony. I trust today's update leaves you as excited as we are for the future as we are making and will continue to make good progress advancing these important clinical trials in cancers where current therapies are woefully inadequate or where life-saving new therapies are greatly needed. Our team remains steadfast in our commitments to advancing our DNAbilize platform technology as we seek to deliver a better path for cancer patients worldwide. With that, operator, we are ready to open the call for questions. Ladies and gentlemen, at this time, we'll begin the question and answer session. To ask a question, you may press star and then one using a touch-tone telephone. To withdraw your questions, you may press star and two. If you are using a speakerphone, we do ask that you please use the keypads to ensure the best sound quality. Once again, that is star and then one to ask a question. Our first question today comes from Yi Chen from H.C. Wainwright & Co. Please go ahead with your question. Thank you for taking my questions. Could you provide an update on the number of enrolled patients in each three cohorts of the phase 2 trial of BP1001? Well, as I think I'd mentioned, you know, we had the trial was slowed down in the last year and a half previously from manufacturing issues related to COVID and just the environment. We have across the cohorts now picked up the enrolling and treating. In fact, we've, I think I'd mentioned that we were doubling our supply chain of the key manufacturing plants, our oligo manufacturer, and then our final drug product manufacturer. That plan is coming to fruition as we are adding more drug supplies and able to treat more patients. That's the principal reason that you saw the R&D expense jump up. I think as we've talked about many times on these calls, as we produce new drug product for treating patients, it accumulates on the balance sheet, prepaid, and then when it's done and released to the company for use in the trial, it drops to an expense. Overall, I'd say, we're about halfway in the cohorts. Some may be a little bit faster than the others. We continue to think that we're looking towards being able to start interim results late in the late fourth quarter or more likely in the first quarter of 2023. At that point, we'll assess, you know, our efficacy and safety and as appropriate, move with the FDA to see if there's any opportunities for expedited programs. Just to clarify, you think the trial will reach 19 evaluable patients for interim analysis at the end of this year or in the first quarter of 2023, correct? Yes, I think that, you know, more it just depends on how quickly we can treat those and get the evaluable patients. You know, that end of it, I think has been going pretty well. 2019, you know, it's safer to say that we'll be in the middle of doing that in the first quarter and evaluating them, so. Got it. During the remainder of 2022, shall we expect to see preliminary data from the phase 1 trial of BP1001-A and BP1002? Well, I think as we indicated, we've completed the work now of getting that trial, both of those trials, open. We've generated, I think a lot of interest in the trial. I think there's six sites for the dash A and three real quality sites for the resistant AML. You know, you can never tell how fast they come in, but, you know, I'd like to think we'd hit at least one cohort for both of those trials in 2022. We'll report on that. Thank you. Lastly, is there any additional preclinical study for BP1003 that needs to be concluded before the drug can enter a clinical trial? I think, you know, of course, we just did the AACR and we are working on a lot of our focus in preclinical right now is on AML, venetoclax resistant cells. So, we may have something coming out on that. So other than that, I really don't wanna reference you know any of our programs. Our research group stays pretty active in doing preclinical work that's supportive of the products that we're trying to advance. Okay. Thank you. Once again, if you would like to ask a question, please press star and one. Our next question comes from Jonathan Aschoff from Roth. Please go ahead with your question. Thank you. I just had one question, Peter. You know, we've seen clinical experience with BP1001, and, you know, you are certainly talking about the difficulty in getting low doses, getting doctors interested in low doses of BP1002. Excuse me, I have COVID. My question is, you know, BP1001-A being, you know, kind of similar to BP1001, do we expect BP1001-A to have that kind of low dose, low enrollment that you're now experiencing and, you know, have been for a while with BP1002? Or can it piggyback at all on the earlier BP1001 experience 'cause it is a highly similar agent? Yeah, the substance is the same too. It's a good question, and you're right. Because of the body and experience we have with prexigebersen, and we're able to start at a higher dose, 60 milligram per square meter. You know, that's the dose in AML. Do a cohort at that and then go on to 90. Yeah, we don't have to go through the low 20 milligram cohorts. That's helpful to know. Did you disclose that earlier, or is that the first time you said that you can start at 60 with, A? It's certainly been in our documents, so I don't know if I Okay. Specifically mentioned that, if I haven't. No. I know documents 'cause, you know, obviously as you pointed out, that's a real feature that we can start out at 60. Yeah. That's helpful to know. Thank you very much, Peter. Ladies and gentlemen, at this time, seeing no additional questions, I would like to turn the conference call back over to Mr. Nielsen for any closing remarks. Thank you again, everyone for joining us and for your continued support of Bio-Path. Have a great day. Bye. Ladies and gentlemen, with that, we'll conclude today's conference call and presentation. We do thank you for joining. You may now disconnect your lines.